Experimental studies indicate significant cardioprotective effects of recombinant erythropoietin (Epo) 
Introduction

Animal studies indicate that recombinant erythropoietin (rEpo) or other erythropoiesis-stimulating agents (ESA) exert cardioprotective effects in ischaemia-reperfusion injury and also in non-ischaemic cardiac dysfunction
, a frequently used anthracycline causing cardiomyopathy in cancer treatment, or after cardiac ischaemic-reperfusion injury [4] . Gata4 regulates genes that are relevant for proper cardiomyocyte integrity and function, such as ␣-myosin heavy chain (␣-Mhc), ␤-Mhc, troponin, atrial natriuretic factor (Anf) and bone morphogenetic protein-4 (Bmp4) [5, 6] . Because Gata4 exhibits direct anti-apoptotic function by regulating genes of the bcl-XL family and other factors [4, 7] , rEpo appears to be an attractive pharmaceutical substance to prevent or even to treat cardiomyopathy via Gata4 restoration [8, 9] . However, rEpo or its derivates have not been tested clinically for anthracycline-induced cardiomyopathy, and the first clinical data on rEpo for the protection against ischaemiareperfusion heart injury are rather disappointing if compared to experimental data [10] .
Because Epo's actions require binding to the extracellular domain of the Epo receptor (EpoR), the question on the regulation of the EpoR gene in cardiomyocytes is of particular interest.
The first evidence for an essential role of Epo and its receptor in the heart resulted from the analysis of transgenic mice with homozygous deletion of the Epo (Epo Ϫ/Ϫ ) or the EpoR (EpoR Ϫ/Ϫ ) genes [11, 12] . Both Epo Ϫ/Ϫ and EpoR Ϫ/Ϫ embryos suffer from ventricular hypoplasia, epicardium detachment and vascular abnormalities [11] . In the murine heart, EpoR is expressed in a temporal and cell type-specific manner. From mid-gestation onwards, EpoR expression has been detected in foetal, neonatal and adult cardiomyocytes [13] [14] [15] [16] . Organ cultures or primary cell cultures from embryonic heart showed that rEpo acts as mild mitogen for cardiomyocytes [11] . In EpoR Ϫ/Ϫ mice that have been rescued from the lethal haematopoietic defect, the endogenous EpoR system is relevant for protection against pressure-overload induced cardiac dysfunction and for protection against myocardial ischemia/reperfusion injury [17, 18] . Although low Epo transcript levels have been detected in the murine embryonic and human foetal heart [11, 14] [20] [21] [22] [23] . However, Gata1 expression is restricted to haematopoietic progenitor cells and Sertoli cells [24] . The analysis of EpoR gene expression in the heart of Wt1-deficient embryos revealed that the transcriptionally active Wt1 protein was not involved in cardiac EpoR expression [23] . Because the transcriptionally active Wt1 protein is expressed exclusively in the epicardium [25] 
Material and methods
Cell culture
The murine cardiomyocyte cell line HL-1 was cultured as described [26] . [29] . pBS/U6-shScram and pBS/U6-shSp1-2 vectors were kindly provided by Grace Gill [30] . 
Animal experiments
RT-PCR
Reporter gene assays
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed with freshly prepared cardiomyocytes from three male 10- 
Western blot analyses
Proteins were extracted from HL-1 cells or murine heart were performed as previously described [28] . 1A ) [19, 20] . This 774 bp fragment (mEpoRpro), spanning from nucleotides (nt) Ϫ674 to ϩ100 relative to the transcription start site (Fig. 1B) [20-23, 32, 33] . Although Epo gene expression was silenced in the developing and adult heart, EpoR transcripts were detected at all stages (Fig. S2) (Fig. 2A) . Of note, the Sp1-specific complex was abolished, if the oligonucleotide that contains only the GC-rich element, but not the GATA-site was incubated with an antibody against Gata4 (Fig. 2A) Fig. 3A) , while forced expression of Gata6 had no effect. In contrast to data in haematopoietic cells [22] [36, 37] . 
previous data on EpoR regulation in haematopoietic cells
In vitro and in vivo binding of Gata4 and Sp1 to the EpoR promoter in cardiomyocytes
To further explore whether Gata4, Gata6 or Sp1 bind to the EpoR promoter, EMSA experiments were carried out with nuclear extracts from HL-1 cells and end-labelled oligonucleotides, which contain regulatory elements of the EpoR promoter. By using antibodies, we identified a Gata4, but not Gata6-specific protein/DNA complex, as well as a Sp1-specific protein/DNA complex
. Thus, Gata4 may be a component of the Sp1-specific complex at the GC-rE. ChIP experiments confirmed that Gata4 as well as Sp1 bind to the EpoR promoter in fresh primary cardiomyocytes (Fig. 2B).
Enhanced EpoR mRNA expression by forced Gata4 expression
The functional implication of Gata4 and Sp1 binding to the EpoR promoter was tested by transient transfection of HL-1 cells. Forty-eight hours after transient Gata4 overexpression a 3-fold stimulation of endogenous EpoR expression was found (P Ͻ 0.05;
, Sp1 overexpression resulted only in a slight, but not significant increase of EpoR mRNA levels in HL-1 cells. Co-transfection of Sp1 with either Gata4 or Gata6 plasmids did also not significantly (further) enhance EpoR expression (Fig. 3A). These data clearly support the role of Gata4 as a positive regulator of EpoR expression in cardiomyocytes. Unfortunately, the analysis of EpoR protein expression could not be performed due to non-specific cross-reactivity of the currently available EpoR antibodies
Decreased EpoR mRNA expression in Gata4 and Sp1 siRNA experiments
Down-regulation of cardiac EpoR expression in transgenic mice with inducible RNA interference directed against Gata4
To study the effect of Gata4 knockdown on endogenous EpoR expression in vivo, we analysed transgenic mice with a stably integrated shRNA against Gata4 under control of the TetR system [27] . To induce the expression of Gata4 shRNA, transgenic mice were fed with doxycycline over 38 days, because this resulted in the most efficient, significant down-regulation of endogenous Gata4 mRNA expression to 10 Ϯ 4 [6, 27] . However, downregulation of Gata4 expression was associated with a significant reduction of EpoR mRNA expression to 20 Ϯ 10% of normal levels (Fig. 4) . In addition, Gata6 levels remained normal in transgenic mice with inducible Gata4 shRNA [27] 
.5% of the level in control mice (P Ͻ 0.01). In our experiments, reduction of Gata4 protein levels was associated with the down-regulation of selective Gata4-downstream targets, such as the genes encoding Anf and Bmp4, but not ␣MHC, and is shown elsewhere [27]. Data from us and others (using conditional cardiac Gata4 deletion) indicated that under non-stress conditions Gata4 depletion of up to 80% of normal levels did not result in cardiac failure
, confirming our data from DNA-binding analysis and overexpression analysis which indicate that Gata6 is not involved in cardiac EpoR regulation (Figs 2 and 3).
Gata4 depletion in doxorubicin-induced cardiomyopathy is associated with decreased EpoR expression
In a more physiological and clinical relevant approach, we studied the role of Gata4 in regulating cardiac EpoR expression in a mouse model of doxorubicin-induced cardiomyopathy. This model is characterized by Gata4 depletion accompanied with cardiomyocyte atrophy, degeneration and myocardial fibrosis [3] . After a single intraperitoneal injection of 15 mg/kg doxorubicin hydrochloride or the equivalent volume of saline for controls, animals were sacrificed 24 hrs or 5 days later. Cardiac Gata4, Gata6 and Sp1 levels were analysed by Western blot analysis. EpoR levels were quantified by Q-PCR (Fig. 5A) [36, 37] . Gata4 and Sp1 knockdowns were verified by immunoblot. significantly decreased (to 19 Ϯ 18% of normal levels) within the first 24 hrs. After 5 days, EpoR mRNA expression recovered in parallel to Gata4 to almost normal levels. Again, Gata6 and Sp1 protein level were unaffected, whereas suppression and later recovery of ␣-Mhc mRNA expression served as bona fide control for the specific Gata4 effect (Fig. 5B and C Fig. 2) . Furthermore, mutation of the GATA-motif results in a reduced activity of the EpoR promoter (Fig. 1) . The combined data from the reporter gene analysis indicate that additional cis-regulatory elements are involved in regulating EpoR promoter activity (Fig. 1) . Our data also confirm that DNA elements in the 5Ј-flanking region of the murine EpoR gene are clearly regulated by both lineage-and temporal-specific mechanisms (Fig. S1 ) [31] . We also show that Sp1 specifically binds to a GC-rich element within the EpoR promoter in cardiomyocytes (Fig. 2) . Although forced expression of Sp1 only slightly stimulates endogenous EpoR expression, Gata4 significantly enhances EpoR mRNA expression (Fig. 3) . In an opposite approach, knockdown of Gata4, but also of Sp1 was associated with a significant down-regulation of EpoR mRNA expression (Figs 3 and 4) (Fig. 4) . In these transgenic mice, some Gata4 downstream targets, such as the genes encoding Bmp4 and Anf, are expressed at lower levels than in wild-type mice, whereas other Gata4 downstream targets such as the ␣-Mhc gene are normally expressed [27] . This phenomenon could be due to differences in the affinity of Gata4 to regulatory elements of the target genes. In this context it is important that Gata6, which has often been discussed to compensate for Gata4 deficiency [5, 6, 39] , is not modulated in the Gata4 shRNA expressing transgenic mice [27] human hearts than in healthy cardiac tissues [40] . Doxorubicin, which is broadly used for cancer treatment, causes irreversible degenerative cardiomyopathy and congestive heart failure [41] , which is associated with Gata4 depletion in wild-type mice [3, 7, 42] . Indeed, Gata4 depletion resulted in a significant down-regulation of EpoR expression, while during the recovery period EpoR mRNA levels normalized with restored Gata4 levels. The specificity of this mechanism is supported by results on the ␣-Mhc expression as bona fide control (Fig. 5) . Of note, in doxorubicin-induced cardiomyopathy Gata4 can be experimentally restored and Gata4 phosphorylation can be increased by rEpo treatment [3, 4] . This process is associated with the induction of the ErK/MAPK signalling pathway [3] . Activation of this pathway stimulates nuclear translocation of the Gata4 protein and increases Gata4 binding to regulatory DNA elements of downstream target genes [35] . Furthermore, activation of the MAPK cascade leads to the phosphorylation of Gata4, which potentates its activity and direct, Epo-independent, cardioprotective effects [7, [42] [43] [44] . Thus [10, 45, 46] .
Analysis of EpoR protein expression could not be performed due to nonspecific cross reactivity of currently available EpoR antibodies
In 
